IgG antibody response to toxins A and B in patients with Clostridium difficile infection

Clin Vaccine Immunol. 2012 Sep;19(9):1552-4. doi: 10.1128/CVI.00210-12. Epub 2012 Jul 11.

Abstract

IgG antibodies against Clostridium difficile toxins A and B were followed in controls and in patients with an initial C. difficile infection (CDI). Of the 50 CDI patients, 38 were cured and 12 developed recurrence. Compared to controls, patients had significantly lower anti-toxin A and B IgGs at inclusion, but the subsequent levels rose slightly regardless of clinical outcome. The results imply that the general serum reactivity against toxins A and B in the population reduces the risk of CDI, which suggests implications for vaccine strategies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Bacterial / blood*
  • Antitoxins / blood*
  • Bacterial Proteins / immunology*
  • Bacterial Toxins / immunology*
  • Clostridioides difficile / immunology*
  • Clostridioides difficile / pathogenicity
  • Clostridium Infections / immunology*
  • Clostridium Infections / microbiology
  • Enterotoxins / immunology*
  • Female
  • Humans
  • Immunoglobulin G / blood*
  • Male
  • Middle Aged
  • Recurrence
  • Treatment Outcome
  • Young Adult

Substances

  • Antibodies, Bacterial
  • Antitoxins
  • Bacterial Proteins
  • Bacterial Toxins
  • Enterotoxins
  • Immunoglobulin G
  • tcdA protein, Clostridium difficile
  • toxB protein, Clostridium difficile